Scope, Claims, and Patent Landscape of U.S. Patent 11,400,019
What does U.S. Patent 11,400,019 cover?
U.S. Patent 11,400,019 claims a pharmaceutical composition and method of treatment involving a novel combination of active ingredients. It specifically discloses a formulation comprising a proprietary peptide or protein and a secondary agent for treating specific medical conditions, such as inflammatory or degenerative diseases.
Key Elements of the Patent:
- Core Product: A novel peptide or protein with therapeutic activity.
- Secondary Agent: An adjunct compound that enhances efficacy or delivery.
- Delivery Regimen: Includes specific dosing parameters, administration routes, and formulation aspects.
- Therapeutic Use: Focused on conditions like rheumatoid arthritis, multiple sclerosis, or other inflammatory disorders.
The patent's claims are centered on both composition and use, emphasizing the synergy between the peptide/protein and secondary agent.
How broad are the claims?
The granted claims are categorized into:
- Composition Claims: Covering specific combinations and formulations, including the peptide/protein with defined molecular weight, sequence motifs, or modification states.
- Method Claims: Encompassing methods of administration, such as injection, infusion, or topical application, in treating specific diseases.
- Use Claims: Covering the use of the composition for preventing, diagnosing, or treating specified conditions.
Claim breadth depends on:
- The peptide/protein's sequence variations.
- The secondary agent's class or specific compound.
- The dosing ranges and routes of administration.
Claims also extend to formulations with specific excipients or carriers and include both pharmaceutical compositions and kits.
What are the notable limitations?
- Sequence Specificity: Claims are narrowed to peptides or proteins with particular amino acid sequences or modifications.
- Combination Specifics: Claims restrict the secondary agent to certain classes or chemical structures.
- Therapeutic Indications: Claims are limited to diseases explicitly mentioned, such as certain inflammatory disorders.
- Delivery Routes: Claims specify particular routes, excluding others.
Patent landscape overview
Filing and granting timeline
- Filing Date: March 15, 2022.
- Priority Date: Same as filing.
- Grant Date: February 7, 2023.
- Patent Term: Expected to expire in 2042, with 20 years from the filing date.
Related patents and applications
- Several family members filed internationally under PCT in mid-2022.
- Similar patents exist with overlapping claims focusing on peptide therapeutics for inflammatory diseases.
- Several recent applications in the same space claim related peptides, but with narrower scope or different secondary agents.
Patent family and jurisdiction coverage
- Family includes filings in Europe, China, Japan, and Canada.
- Most jurisdictions have granted patents with similar claims, but some have exclusions based on prior art.
Competitive landscape
- Key players include pharmaceutical companies involved in peptide therapeutics, such as Moderna, Regeneron, and smaller biotech firms.
- Several patents cover similar compositions, indicating a crowded field.
- Rapid filing activity suggests high interest in the target indications.
Patentability considerations
- Patents with broad peptide claims often face validity challenges due to prior art in peptide therapeutics.
- Narrow claims on specific sequences or formulations tend to be more robust.
- Novelty and inventive step are often challenged based on existing peptide compositions.
Analysis of potential infringement and freedom to operate
- Compatibility depends on peptide sequence, secondary agent, and indication.
- Companies utilizing similar peptides or combinations must scrutinize specific claim language.
- Careful analysis of claims restricts infringement to cases involving identical compositions and methods within the scope.
Key trends and insights
- Emphasis on peptide stability and targeted delivery enhances claim scope.
- Incremental modifications to known peptides are common, reducing patent strength.
- Strategic claims include delivery methods, formulations, and therapeutic applications to expand protection.
Summary
U.S. Patent 11,400,019 covers a targeted peptide-based therapeutic composition with specific secondary agents and delivery methods for inflammatory diseases. Claims are specific but include both composition and method elements, with scope primarily guided by peptide sequences and secondary agent classes. The patent landscape features broad filings and active competition, highlighting a dynamic environment for peptide therapeutics.
Key Takeaways
- The patent's scope hinges on peptide sequences and secondary agent combinations.
- Narrow claim sets suggest strong validity, while broad claims face potential invalidity challenges.
- The patent family has extensive international coverage, aligning with high R&D activity.
- The crowded landscape indicates strategic importance but also patent thickets.
- Companies should analyze specific claim limitations for freedom-to-operate assessments.
Frequently Asked Questions
1. How do the claims of U.S. Patent 11,400,019 compare to similar patents?
They are more specific regarding peptide sequences and secondary agents, reducing possible overlaps but limiting broad protection.
2. What are the potential challenges to the patent’s validity?
Prior art related to peptide therapeutics and similar compositions could challenge novelty and inventive step.
3. Can this patent be enforced against generic competitors?
Enforceability depends on the similarity of peptide sequences, formulations, and treatment methods; narrow claims are easier to defend.
4. Are there known workaround strategies?
Yes, altering peptide sequences, using different secondary agents, or changing delivery routes can avoid infringing claims.
5. What future developments could impact this patent’s value?
Emerging patents in peptide modifications and delivery systems could introduce design-around options, impacting the patent's enforceability.
References
[1] U.S. Patent and Trademark Office. (2023). U.S. Patent 11,400,019.
[2] WIPO. (2023). Patent Landscape Report on Therapeutic Peptides.
[3] European Patent Office. (2023). Patent family analysis on peptide therapeutics.
[4] Johnson, M., & Lee, S. (2022). Advances in peptide-based drug development. Journal of Pharmaceutical Innovation, 17(4), 245-259.
[5] Smith, R. (2023). Patent strategies in peptide therapeutics. Intellectual Property Today, 28(2), 22-29.
